Prof. Dr. Hüseyin Mertsoylu

Formation et spécialisation

• 1992–1999 Faculté de médecine de l’Université Hacettepe, programme en anglais
• 2000–2005 Service de médecine interne, Faculté de médecine de l’Université Gazi
• 2006–2009 Unité d’oncologie médicale du service de médecine interne, Faculté de médecine de l’Université Başkent
• 2009–2011 Service obligatoire comme spécialiste en oncologie médicale à l’Hôpital de formation et de recherche de Şanlıurfa (deux ans)
• 2011–2023 Unité d’oncologie médicale du service de médecine interne, Faculté de médecine de l’Université Başkent
• 19 octobre 2016 Titre de maître de conférences
• 3 décembre 2021 Titre de professeur

Langues étrangères

• Anglais

Affiliations professionnelles

• Société turque d’oncologie médicale
• Société européenne d’oncologie médicale (ESMO)

Publications scientifiques

• Sarıca B, Tufan K, Çekinmez M, Şen O, Önal C, Mertsoylu H, Topkan E, Pehlivan B, Erdoğan B, Altınors N. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.. J Neurosurg Sci, 2010.
• Dişel U, Beşen A, Karadeniz C, Mertsoylu H, Sezer A, Köse F, Sümbül T, Gürkut Ö, Muallaoğlu S, Abalı H, Özyılkan Ö. Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study.. Medical Oncology, 2012.
• Sarıca F, Çekinmez M, Tufan K, Şen O, Önal H, Mertsoylu H, Topkan E, Pehlivan B, Erdoğan B, Altunors MN. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma.. Asian Journal of Neurosurgery, 2012.
• Köse F, Oğuzkurt L, Beşen A, Sümbül T, Sezer A, Karadeniz C, Dişel U, Mertsoylu H, Özyılkan Ö. Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience.. Eur J Radiol, 2012.
• Muallaoğlu S, Dişel U, Mertsoylu H, Beşen A, Karadeniz C, Sümbül T, Abalı H, Özyılkan Ö. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.. Journal of Balkan Union of Oncology, 2013; 18:261-267.
• Köçer NE, Köse F, Karaselçuk F, Beşen A, Mertsoylu H, Özyılkan Ö, Tuncer I. Does Fascin Expression in Diffuse Large B-Cell Lymphomas have a Clinical Impact in Patients Treated with Anthracyclin-Based Chemotherapy Plus Rituximab?. uhod, 2013.
• Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S, Özyılkan Ö. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. int urol nephrol, 2014.
• Muallaoğlu S, Karadeniz C, Mertsoylu H, Beşen AA, Sezer A, Sedef AM, Köse F, Özyılkan Ö. The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer. J BUON, 2014.
• Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Özyılkan Ö. Malignant pleural mesothelioma: a single-center experience in Turkey. med sci monit, 2014.
• Muallaoğlu S, Beşen AA, Ata A, Mertsoylu H, Arıcan A, Kayaselçuk F, Özyılkan Ö. Lack of prognostic significance of C- erbB-2 expression in low- and high- grade astrocytomas. Asian Pacific journal of cancer prevention, 2014.
• Mertsoylu H, Muallaoğlu S, Besen AA, Erdoğdu S, Sezer A, Sedef AM, Köse F, Arıcan A, Özyılkan Ö. Primary extranodal non-Hodgkin’s lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey. Asian Pac J Cancer Prev. 2014;15(17):7207–7211. doi:10.7314/apjcp.2014.15.17.7207.
• Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Muallaoğlu S, Köse F, Özyılkan Ö. Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.. Hepatogastroenterology., 2014.
• Sedef AM, Köse F, Sümbül AT, Doğan Ö, Beşen AA, Tatlı AM, Mertsoylu H, Sezer A, Muallaoğlu S, Özyılkan Ö, Abalı H. Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. Med Oncol., 2015.
• Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Beşen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.. Med Sci Monit, 2015.
• Sedef AM, Köse F, Sümbül T, Doğan Ö, Kurşun E, Yurdakul Z, Sümbül G, Mertsoylu H, Sezer A, Özyılkan Ö. Prognostic value of procalcitonin in infection-related mortality of cancer patients. J BUON, 2016.
• Parlak C, Mertsoylu H, Güler OC, Önal C, Topkan E. Definitive Chemoradiation Therapy Following Surgical Resection or Radiosurgery Plus Whole-Brain. International Journal of Radiation Oncology*Biology*Physics, 2016.
• Temi Bakkal Y, Mertsoylu H. A study on basic demographic and disease characteristics of cancer-diagnosed Syrian refugees treated in the border city of Turkey, Sanliurfa; a hospital-based retrospective case series study.. J BUON., 2017
• Topkan E, Mertsoylu H. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.. J Neurooncol., 2018.
• Muallaoğlu S, Karagün Ö, Mertsoylu H, Beşen AA, Sezer A, Özyılkan Ö. Attributes of cancer patients admitted to the emergency department in one year. World J Emerg, 2018.
• Topkan E, Mertsoylu H. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non- small cell lung cancer.. Lung Cancer, 2018.
• Önal HC, Mertsoylu H. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. Int J Gynecol Cancer., 2018.
• Topkan E, Mertsoylu H. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients. Journal of oncology, 2018.
• Topkan E, Mertsoylu H. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy. Journal of geriatric oncology, 2019.
• Topkan E, Mertsoylu H. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy. Ear, Nose & Throat Journal, 2019.
• Önal HC, Mertsoylu H. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Future Oncology, 2019.
• Yıldırım B, Mertsoylu H. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Strahlentherapie und Onkologie, 2019.
• Topkan E, Mertsoylu H. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy. The International journal of biological markers, 2019.
• Topkan E, Mertsoylu H. Pretreatment Photopenia on 18 F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomograpy Scans Predicts Poor Prognosis in Nasopharygeal Cancer Patients Undergoing Concurrrent Chemoradiotherapy. Clinical Expiremental Otorhinolarngology, 2019.
• Topkan E, Mertsoyul H. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy. cancer management and research, 2019.
• Topkan E, Mertsoylu H. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients. PloS one, 2019.
• Özdemir Y, Topkan E, Mertsoylu H, Selek U. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy. Cancer Manag Res. 2020;12:1959–1967. doi:10.2147/CMAR.S248034.
• Topkan E, Mertsoylu H. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators of Inflammation, 2020.
• Topkan E, Mertsoylu H. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. International Journal of Inflammation, 2020.
• Köse F, Mertsoylu H. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse. Eur.?J.?Gynaecol.?Oncol, 2020.
• Topkan E, Mertsoylu H. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. Journal of Immunology Research, 2020.
• Topkan E, Mertsoylu H. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma□ Patients Treated with Definitive Concurrent Chemoradiotherapy. Journal of Oncology, 2020;
• Topkan E, Mertsoylu H. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy:A Propensity Score Matching Study. Journal of Oncology, 2020.
• Topkan E, Mertsoylu H. Low Systemic Inflammation Response Index Predicts Good PrognosTreated with Concurrent Chemoradiotherapyis in Locally Advanced Pancreatic Carcinoma Patients. Gastroenterology Research and Practice, 2020.
• Köse F, Mertsoylu H. Clinical Charactestics of Relapsed Ovarioan Cancer Patients with Striking Response to the Bevasiumab an First Relapse. European Journal of Gynaecological Oncology, 2020.
• Köse F, Mertsoylu H. Half Dose Bevasizumab Experiience in Relapsed Overian Cancer Patients in Turkey due to Formal Regulation. JBUON, 2020.
• Sezgin Göksü S, Mertsoylu H. Cetuximab?induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck□. Cancer Chemotherapy and Pharmacology, 2021.
• Abalı H, Mertsoylu H. A Phase II Study of the Combination of OxaliplatinCapecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study). American Journal of Clinical Oncology, 2021;

Sélection de publications scientifiques

• Yilmaz B, Somay E, Topkan E, Pehlivan B, Besen AA, Mertsoylu H, Selek U. Predictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomas. J Stomatol Oral Maxillofac Surg. 2024;125(6):101786. doi:10.1016/j.jormas.2024.101786.